Archive — US — techcrunch
Catalio Capital closes over $400M Fund IV
Catalio Capital Management has closed its over $400 million Fund IV, focusing on healthcare and biotechnology investments. Founded in 2020, the firm has made over 100 investments and backed 16 companies with Fund IV despite a downturn in the biotech market due to higher interest rates and a weaker IPO environment.
Key points
- Catalio Capital Management closed Fund IV with over $400 million.
- The firm focuses on healthcare and biotechnology investments.
- Founded in 2020, it has made more than 100 investments to date.
- Fund IV has already backed 16 companies, including PinkDx and Superluminal Medicines.
- Catalio previously raised $381 million in Fund III (2020) and $100 million in Fund II (2019).
- The overall biotech market raised only $12 billion last year, a decline from $152.3 billion in 2023.
Why it matters
- The venture capital industry is experiencing a downturn due to rising interest rates.
- The IPO market cooling has impacted fundraising capabilities within biotech.
- Historically, the venture capital market peaked in 2021-2022, highlighting cyclical trends.
Catalio's closure of its Fund IV amid market challenges underscores the persistent demand for healthcare innovations, reinforcing its commitment to the biotech sector despite broader venture capital declines.